Major study links cefepime to higher mortality risk across 110 clinical trials

Beta-lactam antibiotics anchor the frontline treatment of serious bacterial infections in hospitals worldwide. A study published in JAMA Network Open found that cefepime, one of the most widely used drugs in that class, carried a higher rate of all-cause mortality than other beta-lactam comparators across 110 randomized clinical trials and more than 22,000 patients.

The mortality gap was narrow but consistent. Among 11,726 patients given cefepime, 778 deaths occurred within approximately 30 days of treatment, a rate of 6.6%. Patients given other beta-lactam antibiotics died at a rate of 6.2%. Using a Bayesian meta-analysis, researchers placed a 94.4% probability on cefepime being associated with higher all-cause mortality across the full dataset. When the analysis was restricted to 73 peer-reviewed published trials, that probability rose to 98.6%.

The dosing problem at the center of the finding

The association appeared across patient groups but was most pronounced among adults, particularly those treated for febrile neutropenia, a medical emergency involving fever and critically low white blood cell counts. Patients with kidney problems and older adults were identified as especially susceptible to severe side effects, which can include confusion, decreased consciousness, and seizures.

Researchers offered several possible explanations for the mortality differential without identifying a single cause. Two they cited: drug levels too low to clear the infection, and neurotoxicity arising when levels become too high. Finding the right dose is complicated, because higher doses may improve the drug's ability to fight bacteria while also raising the risk of toxic effects.

Despite the findings, the researchers stopped short of recommending that clinicians discontinue cefepime. They called for additional guidance and further research into its safety profile.

Dr. Marc Siegel, a Fox News senior medical analyst who was not involved in the research, said the study shows the value of re-examining older evidence. Siegel noted that febrile neutropenia is itself a major cause of death in affected patients, making it difficult to separate the drug's contribution from that of the underlying condition. He suggested that both underdosing and overdosing may be more closely linked to worse outcomes than the drug itself, and raised the possibility of a role for artificial intelligence in determining correct dosing and assessing patient outcomes.

The study's limitations bear on its conclusions. The trials combined differed in design, patient populations, dosing strategies, and comparison antibiotics, with some dating back decades. The analysis identified an association, not proof that cefepime caused the higher mortality.